Karyopharm Therapeutics Inc.
KPTI
$5.46
$0.101.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.57% | -11.35% | -9.39% | -9.50% | 7.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.57% | -11.35% | -9.39% | -9.50% | 7.70% |
| Cost of Revenue | -12.76% | -15.05% | -3.80% | -10.95% | 2.66% |
| Gross Profit | 744.11% | 38.64% | -40.24% | 5.71% | 396.48% |
| SG&A Expenses | -3.71% | -8.35% | -7.44% | -11.40% | -10.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.92% | -12.11% | -5.40% | -13.60% | -3.27% |
| Operating Income | 42.09% | 13.28% | 1.49% | 17.26% | 15.92% |
| Income Before Tax | -3.27% | -255.97% | 37.18% | 25.94% | 7.10% |
| Income Tax Expenses | 21.43% | -40.30% | -49.30% | -183.85% | 133.33% |
| Earnings from Continuing Operations | -3.29% | -256.57% | 37.20% | 26.43% | 7.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.29% | -256.57% | 37.20% | 26.43% | 7.05% |
| EBIT | 42.09% | 13.28% | 1.49% | 17.26% | 15.92% |
| EBITDA | 42.37% | 13.27% | 1.47% | 17.31% | 15.97% |
| EPS Basic | 0.68% | -291.06% | 32.98% | 32.92% | 14.96% |
| Normalized Basic EPS | 0.69% | -67.13% | 42.90% | 32.47% | 15.01% |
| EPS Diluted | 0.68% | -45.40% | 32.98% | 32.37% | 14.96% |
| Normalized Diluted EPS | 0.69% | -113.22% | 42.90% | 32.47% | 15.01% |
| Average Basic Shares Outstanding | 3.99% | 6.83% | 10.01% | 9.67% | 9.30% |
| Average Diluted Shares Outstanding | 3.99% | -16.27% | 10.01% | 9.67% | 9.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |